[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100588161":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":28,"centralContacts":33,"locations":39,"responsibleParty":56,"collaborators":10,"id":58,"slug":59,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":64,"eligibilityCriteria":65,"healthyVolunteers":60,"sex":66,"minAge":67,"maxAge":10,"enrollmentInfo":68,"targetDuration":10,"studyType":71,"phases":10,"briefSummary":72,"conditions":73,"keywords":75,"overallStatus":42,"whyStopped":10,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":89},{"fullName":5,"class":6},"Technische Universität Dresden","OTHER",[8,13],{"label":9,"type":10,"description":10,"interventionNames":11},"Upadacitinib (treatment group)",null,[12],"Drug: Upadacitinib",{"label":14,"type":10,"description":10,"interventionNames":15},"Dupilumab (active comparator)",[16],"Biological: Dupilumab",[18,23],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":10},"DRUG","Upadacitinib","30 mg tablet daily",[9],{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":10},"BIOLOGICAL","Dupilumab","300 mg injection every other week",[14],[29],{"name":30,"affiliation":31,"role":32},"Jochen M Schmitt","Center for Evidence-based Healthcare, Medical Faculty and University Hospital Carl Gustav Carus, Technische Universität Dresden","PRINCIPAL_INVESTIGATOR",[34],{"name":35,"role":36,"phone":37,"phoneExt":10,"email":38},"Thomas Birkner","CONTACT","+4935145889937","Thomas.Birkner@ukdd.de",[40],{"facility":41,"status":42,"city":43,"state":44,"zip":45,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"Center for Evidence Based Health Care","RECRUITING","Dresden","Saxony","01307","Germany","DE",{"type":49,"coordinates":50},"Point",[51,52],13.73832,51.05089,{"lat":52,"lon":51},[55],{"name":35,"role":36,"phone":37,"phoneExt":10,"email":38},{"type":57,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100588161","replication-of-the-heads-up-atopic-dermatitis-trial-with-registry-data-100588161",false,"NCT06937788","Replication of the Heads Up Atopic Dermatitis Trial With Registry Data","Pragmatic Replication of the Heads Up Head-to-head Study of Upadacitinib and Dupilumab With TREATgermany Registry Data","Re-HU-TREAT","Inclusion Criteria:\n\n* Chronic AD with onset of symptoms at least 3 years prior to baseline\n* Meets UK working party criteria\n* EASI score ≥ 16\n* ≥ 10% body surface area (BSA) of AD involvement at baseline (\"therapy start\") visit\n\nExclusion Criteria:\n\n* contraindications according to upadacitinib or dupilumab labeling","ALL","18 Years",{"count":69,"type":70},240,"ESTIMATED","OBSERVATIONAL","The goal is the replication of the primary outcome (EASI 75 at week 16) of the Heads Up trial (Blauvelt, A, Teixeira, H, Simpson, E et al (2021) doi:10.1001\u002Fjamadermatol.2021.3023) and the evaluation of the patient reported outcomes (POEM, DLQI and RECAP) in a head-to-head comparison of upadacitinib versus dupilumab treatment in moderate-to-severe atopic dermatitis (AD).",[74],"Atopic Dermatitis",[76,77,78,79],"observational","target trial emulation","dupilumab","upadacitinib","2025-08-20",{"date":82,"type":83},"2025-08-21","ACTUAL",{"date":85,"type":83},"2021-08-02",{"date":87,"type":70},"2025-12-31",{"name":5,"class":6},1]